Endothelial Nitric Oxide Synthase Gene Polymorphism and Acute Myocardial Infarction
Author(s) -
Kiyoshi Hibi,
Tomoaki Ishigami,
Kouichi Tamura,
Shunsaku Mizushima,
Nobuo Nyui,
Takayuki Fujita,
Hisao Ochiai,
Masami Kosuge,
Yasujirou Watanabe,
Yuzuru Yoshii,
Minoru Kihara,
Kazuo Kimura,
Masao Ishii,
Satoshi Umemura
Publication year - 1998
Publication title -
hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.986
H-Index - 265
eISSN - 1524-4563
pISSN - 0194-911X
DOI - 10.1161/01.hyp.32.3.521
Subject(s) - medicine , myocardial infarction , cardiology , genotype , enos , coronary artery disease , gene polymorphism , nitric oxide synthase , coronary atherosclerosis , polymorphism (computer science) , endothelial dysfunction , nitric oxide , gastroenterology , gene , genetics , biology
Recently a point mutation of guanine to thymine at nucleotide position 1917 in the endothelial nitric oxide synthase (eNOS) gene has been reported to be associated with coronary artery spasm. In addition, a significant association of the 4a/b polymorphism in intron 4 of the eNOS gene with coronary artery disease has been reported. However, the implications of these polymorphisms with respect to acute myocardial infarction (AMI) remain to be established. We conducted a case-control study of 226 patients with AMI and 357 healthy gender- and age-matched control subjects. In the former group, coronary angiograms were evaluated according to angiographic criteria based on the number of diseased vessels (>/=75%) and the number of stenotic lesions (>/=50%). Homozygosity for the Glu-Asp298 polymorphism existed in 5 of 226 patients with AMI (2.2%) but not in any of the 357 control subjects (P=.0085). However, when we evaluated the coronary angiograms of 226 case patients, there was no difference in the number of diseased vessels or the number of stenotic lesions between the patients with this homozygote and those without it. By contrast, there was no evidence of a significant increase in the risk of AMI or the severity of coronary atherosclerosis among individuals with the a/a genotype of the eNOS4a/b polymorphism. Our results imply that patients who are homozygous for the Glu-Asp298 polymorphism may be genetically predisposed to AMI; however, this mutation apparently is not related to the severity of coronary atherosclerosis. Further studies are needed to confirm our results and characterize the molecular mechanisms by which eNOS is involved in susceptibility to AMI.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom